XML 30 R21.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)
€ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2024
EUR (€)
entity
Dec. 31, 2023
General principles and statement of compliance    
Number of entities being consolidated | entity 2  
Hepalys Pharma, Inc    
General principles and statement of compliance    
Proportion of ownership interest 14.64% 15.00%
Inventiva Inc.    
General principles and statement of compliance    
Percent of ownership interest 100.00%  
Non-controlling interest | € € 0